tbuckley/cabot-search huggingface dataset:
Abstract 15527: Current Population Incidence and Survival From Out-of-Hospital Cardiac Arrest in a Norwegian Region With Complete Follow-Up
Authors: Jon E Steen-Hansen, Trond Thoresen, Eirik Skogvoll
Journal: Circulation (2016)

Introduction:  Population measures of cardiac arrest incidence and survival are important components of the chain of survival, and thus useful for community emergency medical service (EMS) planning and benchmarking. The Norwegian unique person identification number allows for complete case tracking and follow-up. Aims of this study were to report relevant population statistics, including trends over the last 9 years, for out-of-hospital cardiac arrest in a modern EMS with a well-established cardiac arrest registry.   Methods:  All resuscitation attempts by the EMS in Vestfold and Telemark (mixed urban/rural area 5 830.9 mi 2  [15 102 km 2 ] with average population 369 000; 3 325 202 person-years) from 2007 to 2015 were included. The Norwegian bureau of statistics supplied age-specific population data. Confidence intervals were calculated and trends were investigated using Poisson regression.   Results:  Over 9 years, the EMS attempted resuscitation in a total of 2013 patients with cardiac arrest outside hospital. Among these, 558 (28 %) achieved stable return of spontaneous circulation (ROSC) resulting in hospital admission; 271 (13 %) were ultimately discharged. The overall population incidence was 60.5 per 100 000 person-years (95% CI: 57.9 to 63.2) and the incidence of survival to discharge 8.1 per 100 000 person-years (95 % CI: 7.2 to 9.2). The incidence rose markedly with age (figure, with 95 % CI). No time trends were observed with respect to neither incidence nor survival (p =0.9 and p= 0.2, respectively). The prevalence of initial shockable rhythms (VF or VT) was 24 % on average and decreased slightly by 1.4 % per year (p = 0.04).   Conclusions:  The observed population incidence of out-of-hospital cardiac arrest in our region suggests an annual burden of more than 3000 victims in Norway. While shockable rhythms may be declining, other trends were not observed over the last 9 years. Thirteen percent overall survival is relatively high by international standards.
Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis
Authors: Cen Xie, Tomoki Yagai, Yuhong Luo, Xianyi Liang, Tao Chen, Qiong Wang, Dongxue Sun, Jie Zhao, Sadeesh K Ramakrishnan, Lulu Sun, Chunmei Jiang, Xiang Xue, Yuan Tian, Kristopher W Krausz, Andrew D Patterson, Yatrik M Shah, Yue Wu, Changtao Jiang, Frank J Gonzalez
Journal: Nature Medicine (2017)
BMA calls for urgent meeting with health secretary over GP crisis
Authors: Jacqui Wise
Journal: BMJ (2017)

The BMA has written to England’s health secretary, Jeremy Hunt, calling for an urgent meeting to discuss the pressures facing general practice and warning that practices could be forced to close their lists to new patients.

The move follows Hunt’s speech at the Conservative Party conference in Manchester on 3 October, which the BMA criticised for offering no immediate, practical solutions to problems such as increased patient demand and widespread …
The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer
Authors: D. Naruge, C. Morizane, M. Ueno, H. Takahashi, Y. Kawamoto, K. Sudo, S. Shimizu, T.E. Nakajima, S. Itoh, H. Ishii, T. Kato, T. Kudo, M. Izumi, T. Sudo, S. Nomura, T. Kuwata, S. Fujii, K. Shitara, A. Ohtsu, T. Yoshino
Journal: Annals of Oncology (2017)
La tuberculose au Portugal : l'évolution jusqu'en 1994
Authors: M L Antunes, A Fonseca-Antunes
Journal: Eurosurveillance (1996)

Le premier hopital portugais consacre a la tuberculose (TB) fut construit a Funchal, Madere, en 1862. En 1899, la reine Amelia fondait et financait une fondation privee, regroupant des dispensaires, des hopitaux, des sanatoriums et des preventoriums pour suivre les proches ou les personnes ayant ete au contact de sujets tuberculeux et eventuellement les traiter. Cette fondation est devenue une institution publique en 1946. La lutte contre la tuberculose a toujours beneficie d'un soutien politique, social et public qui a permis que tous les services, y compris les nouveaux medicaments, soient fournis gratuitement : la streptomycine a ete introduite en 1949, la rifampicine en 1966 et la chimiotherapie courte en 1979.
Standardized mortality ratios and event-free survival as new prediction tools of early increase in mortality in follicular lymphoma
Authors: F. Franco, A. Royuela, M. Torrente, J. Gómez-Codina, M. Llanos Rodríguez, J. Gumá Padró, C. Quero Blanco, D. Aguiar, A. Rueda Domínguez, M. Provencio Pulla
Journal: Annals of Oncology (2017)
Clinical implication of PLR and PD-L1 in breast cancer patients
Authors: S. Wang, Q. Lu, T. Qin, F. Xu, Y. Zeng, W. Xia, Q. Zheng, K. Lee, K. Zhang, G. Qin, M.T. Kong, R. Hong, Y. Shi, Z. Yuan
Journal: Annals of Oncology (2017)
GW28-e0638 Systematic Correlation of Environmental Exposure with Lower Extremity Peripheral Artery Disease: An Environment-Wide Association Study
Authors: Xiaodong Zhuang, Yanbo Shen, Yue Guo, Ao Ni, Yunxi Jiang, Xueqin Wang, Xinxue Liao
Journal: Journal of the American College of Cardiology (2017)
Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop
Authors: S. Hessam, M. Sand, T. Gambichler, M. Skrygan, I. Rüddel, F.G. Bechara
Journal: British Journal of Dermatology (2017)

Possible regulatory involvement of the interleukin (IL)-36 family in inflammatory diseases has been suggested.To analyse the expression of IL-36α, IL-36β, IL-36γ and the antagonistic cytokines IL-36 receptor agonist (IL-36Ra), IL-37 and IL-38 in the skin of patients with hidradenitis suppurativa (HS).Skin samples from lesional and corresponding perilesional HS skin, and from healthy controls were included in this study and analysed by quantitative real-time reverse-transcriptase polymerase chain reaction (PCR). To evaluate the PCR results of IL-36α, IL-36β and IL-36γ, a subset of skin samples was studied by immunohistochemistry.Expression levels of IL-36α, IL-36β, IL-36γ and IL-36Ra were all significantly higher in lesional HS skin than in healthy controls. IL-37 and IL-38 levels were significantly higher in perilesional HS skin than in healthy controls and were decreased in lesional HS skin. Limitations of the study are its descriptive nature and the small sample size.Our results showed a possible involvement of IL-36 cytokines in the inflammatory network of HS and a dysbalance between the agonistic and antagonistic cytokines in HS skin.
Phase I, open-label, dose-finding study of GSK2636771, a phosphoinositide 3-kinase (PI3K)β inhibitor, in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer (mCRPC)
Authors: P. Rescigno, J. de Bono, A. Aparicio, S. Chowdhury, P. Twardowski, N. Dawson, U. Vaishampayan, A.J. Pantuck, Y. Zhou, D. Fecteau, G. Ganji, J. Tolson, D.A. Smith, J. Medina, L. Yan
Journal: Annals of Oncology (2017)
Tatuajes, maquillaje permanente y piercings en Amsterdam ; recomendaciones, normativas y vigilancia
Authors: J Worp, A Boonstra, R A Coutinho, J A R van den Hoek
Journal: Eurosurveillance (2006)

El tatuaje, los piercings y el maquillaje permanente estan volviendose cada vez mas populares. En este articulo se describen los metodos utilizados en esas tecnicas y los riesgos asociados, las recomendaciones del Servicio municipal de salud de Amsterdam, Paises-Bajos, para reducir los riesgos de infecciones, las leyes de la ciudad de Amsterdam, y el resultado de la vigilancia de los estudios de tatuaje y de piercing.
Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476)
Authors: N. James, J. de Bono, M.R. Spears, N.W. Clarke, M.D. Mason, D. Dearnaley, A.W.S. Ritchie, M. Russell, C. Gilson, R. Jones, S. Gillessen, D. Matheson, S. Aung, A. Birtle, S. Chowdhury, J. Gale, Z. Malik, J. O'Sullivan, M.K. Parmar, M.R. Sydes
Journal: Annals of Oncology (2017)
Prostate-Specific Membrane Antigen in Low-Grade Fibromatosis
Authors: Ramin Akbarian Aghdam, Masoumeh Hakiminejad, Hamidreza Hashemifard, Azadeh Rakhshan, Elahe Pirayesh
Journal: Clinical Nuclear Medicine (2017)

We report a case of fibromatosis demonstrating prostate-specific membrane antigen (PSMA)–positive scan. A 76-year-old man was under assessment because of rising prostate-specific antigen level. Bone scan showed abnormal soft tissue uptake of 99mTc-MDP adjacent to the right scapula, compatible with a mass in MRI, thereafter. Because of the unavailability of 68Ga-PSMA scan in our department and also high cost in other centers, the patient underwent 177Lu-PSMA for more assessment, which revealed PSMA-avid mass. Pathologic examination confirmed the diagnosis of low-grade fibromatosis. This report demonstrates another false-positive result of PSMA scan and highlights the importance of pathologic examination.
Prevención de la infección por rubéola congénita: un desafío para todos los países europeos
Authors: N Crowcroft, R G Pebody
Journal: Eurosurveillance (2004)

Esta edicion de Eurosurveillance contiene el tema compartido de la epidemiologia y el control de la infeccion por rubeola congenita (IRC) en Europa. Constituye un escueto recordatorio de que, pese a que desde hace muchos anos existe una vacuna segura y eficaz, la IRC - la consecuencia de una infeccion por rubeola durante el embarazo -, sigue siendo un importante problema para la salud publica tanto de la Union Europea como del resto de la Region Europea de la OMS. Los articulos a continuacion describen los diversos retos operativos que deben afrontar los programas de inmunizacion de los paises europeos. Ponen claramente de manifiesto las grandes diferencias de carga de la enfermedad y las desigualdades de acceso a los servicios de salud preventivos entre los paises y dentro de cada pais.
Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trial
Authors: T.K. Choueiri, R. Jakacki, D. Ghiorghiu, V. Haddad, A. Kohlmann, M.M. Frigault, L. Ottesen
Journal: Annals of Oncology (2017)
A phase II trial of mirvetuximab soravtansine in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) including a lead-in cohort to establish activity in patients with metastatic TNBC
Authors: S. Damodaran, F. Symmans, T. Helgason, E.A. Mittendorf, D. Tripathy, K. Hess, J. Litton, S. Moulder
Journal: Annals of Oncology (2017)
Abstract 12626: Co-Injection of Induced Pluripotent Stem Cell-Derived Endothelial Cells With Shear Thinning Hydrogel Enhances Survival and Angiogenesis in a Murine Model of Peripheral Arterial Disease
Authors: Ngan F Huang, Lei Cai, Ruby Dewi, Zachary Strassberg, Abbygail Foster, Luqia Hou, Sarah C Heilshorn
Journal: Circulation (2016)

Introduction: Human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) are a promising cell source for enhancing blood perfusion for treatment of peripheral arterial disease (PAD). However, poor cell survival is a critical bottleneck to the efficacy of stem cell therapy. Hypothesis: We hypothesize that encapsulation of cells within an injectable shear-thinning hydrogel with controllable properties will prolong cell survival under ischemic conditions and maintain cellular phenotype, in comparison to cell injection in saline. Methods: The protein hydrogel is comprised of two complementary engineered proteins that self-assemble upon simple mixing. The hydrogel network incorporates a polyethylene glycol physical crosslinker that modulates hydrogel stiffness and degradation. Bioluminescent iPSC-ECs were encapsulated within the hydrogel with controllable stiffness ( G’ ~10-800 Pa) under conditions of hypoxia (1% O 2 ). The cells within hydrogel were then subjected to an in vitro model of injection and assayed for cell survival, proliferation, and endothelial phenotype for up to 14 days. To verify these results in an experimental model of PAD, 10 6 cells were injected in saline or in 400 Pa hydrogel into the ischemic limb of SCID mice for assessment of cell viability and blood flow recovery. Results: Acutely after injection in vitro , cell survival in saline was 65%, in comparison to 94% in hydrogels with stiffnesses of 10-800 Pa. Bioluminescence imaging demonstrated the highest cell proliferation in the hydrogel with 400 Pa stiffness after 14 days. In the 400 Pa hydrogel, iPSC-ECs maintained elongated morphology with robust expression of endothelial phenotypic marker, CD31. In the ischemic hindlimb, iPSC-EC retention was markedly increased when encapsulated in the 400 Pa hydrogel, compared to saline delivery. Concomitantly, mean blood perfusion recovery in the ischemic limb after 14 days was 0.68 when treated with cells in hydrogel, in contrast to 0.61 when cells were injected in saline. Conclusions: These findings demonstrate that stem cell encapsulation within the 400 Pa protein hydrogel improves cell viability and blood perfusion, which may have therapeutic benefit for treatment of PAD.
Interrogating functional dependencies between genomic alterations can facilitate precision medicine approaches in cancer
Authors: M. Mina, F. Raynaud, D. Tavernari, E. Battistello, S. Sungalee, S. Saghafinia, T. Laessle, F. Sanchez-Vega, N. Schultz, E. Oricchio, G. Ciriello
Journal: Annals of Oncology (2017)
La sorveglianza europea della malattia dei legionari associata ai viaggi
Authors: C Joseph
Journal: Eurosurveillance (2004)

Una malattia acquisita in un paese ma diagnosticata e notificata in un altro richiede una cooperazione internazionale per il suo controllo e per intraprendere le indagini atte a prevenire ulteriori casi. Il sistema europeo per la sorveglianza della malattia dei legionari associata ai viaggi (EWGLINET) e stato istituito nel 1987 per rispondere a situazioni di questo tipo ed ha dimostrato la sua efficacia nel diffondere le informazioni e nel coordinare gli interventi.
La Maladie de Creutzfeldt-Jakob : résultats d’une enquête auprès des quinze Etats membres de l’Union Européenne
Authors: B. C. Merkel, P. W.J Peters, L Chambaud
Journal: Eurosurveillance (1996)

La Maladie de Creutzfeldt-Jakob (MCJ) a ete decrite pour la premiere fois en 1920-1921. La MCJ est une maladie rare, avec une incidence rapportee de 0,5 a 1 cas par million d’habitants en Europe (1). Cette demence fatale appartient a la categorie des Encephalopathies Spongiformes Transmissibles (EST) qui comprennent chez l’homme le syndrome de Gerstmann-Straussler-Scheinker, le kuru et l’insomnie fatale familiale, maladies qui surviennent de facon exceptionnelle. Les EST constituent un groupe de maladies subaigues degeneratives du cerveau, dues a des agents filtrables “non conventionnels”, avec des periodes d’incubation tres longues et sans reponse inflammatoire ou immunitaire decelable” (2). Cette maladie survient le plus souvent sous forme sporadique, bien que, dans approximativement 10% des cas, une origine genetique soit trouvee. La MCJ a ete egalement retrouvee apres greffe d’organes ou traitement par des hormones de croissance prelevees chez des cadavres atteints de MCJ.
La seguridad de los bancos de sangre y la prueba de ácidos nucleicos (NAT) en Europa
Authors: S Laperche
Journal: Eurosurveillance (2005)

En las dos ultimas decadas, se han introducido una larga serie de medidas, especificas o no, en el cribado de las donaciones sanguineas para reducir el riesgo residual de transmision de infecciones virales. La prueba de los acidos nucleicos (NAT, nucleic acid testing) es la ultima medida especifica, introducida en 1995 por la industria de plasma y posteriormente utilizada en las donaciones sanguineas en varios paises de Europa o fuera de Europa. Se implemento el NAT para responder a la necesidad de reforzar la seguridad de los bancos de sangre, ya que esta prueba permite detectar durante el periodo de “ventana serologica” las infecciones viricas agudas que no eran detectadas por los metodos de cribado convencionales. Las estimaciones de los riesgos residuales de infecciones viricas transmitidas por la sangre son esenciales para evaluar el impacto de esta nueva prueba de cribado en la seguridad de los bancos de sangre. En esta edicion, seis paises Europeos (Francia, Alemania, Italia, Espana, Suiza y el Reino Unido), en los que se ha implementado el NAT recientemente, describen su experiencia y el resultado de la evaluacion de los riesgos residuales de infecciones viricas en sus hemoderivados [1-6].
A phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy
Authors: P. Komarnitsky, H-J. Lee, M. Shah, S. Wong, S. Gulbranson, J. Dziubinski, L. Caffrey, P. Tanwani, M. Motwani, F. Zhang
Journal: Annals of Oncology (2017)
Report on ESMO/SIOPE European Landscape project key results: Mapping the status and needs in AYA cancer care
Authors: E. Saloustros, D. Stark, K. Michailidou, G. Mountzios, L. Brugières, F.A. Peccatori, S. Jezdic, S. Essiaf, J-Y. Douillard, S. Bielack
Journal: Annals of Oncology (2017)
Phase I study of TAS-121, a novel third-generation epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Authors: H. Murakami, Y. Ohe, T. Hida, H. Sakai, K. Kasahara, F. Imamura, T. Baba, K. Kubota, Y. Hosomi, T. Shimokawa, H. Hayashi, K. Miyadera, T. Tamura, M. Nishio
Journal: Annals of Oncology (2017)
Colonic thioguanine pro-drug: Investigation of microbiome and novel host metabolism
Authors: Timothy Florin, Ramya Movva, Jakob Begun, John Duley, Iulia Oancea, Páraic Ó. Cuív
Journal: Gut Microbes (2017)

Thiopurines are analogues of endogenous purines. They are pro-drugs which require the purine salvage pathway to convert them to the active drug nucleotides (TGN). These drugs are used to maintain clinical remission in patients with inflammatory bowel diseases. In our recent Gut paper, we showed that thioguanine worked quickly to improve colitis in the absence in the host animal of the key guanine salvage enzyme, hypoxanthine-guanine-phosphoribosyltransferase (HPRT). Current evidence favours the proposition that active drug delivery to the host lacking HPRT requires translocation of TGN-loaded bacteria across the inflamed mucosal barrier, and most likely delivery by phagocytosis. Alternatively, the efficacy of thioguanine in treating colitis could be mediated by modulation of the community of the microbiota in the intestine, or there are novel host pathways for conversion of the thioguanine pro-drug to TGN.
Prospective study assessing the expression of angiogenesis-related genes as markers of anti-VEGFR2 response in advanced renal cell carcinoma
Authors: J. Garcia-Donas, N. Lainez, M. Santos-Romero, J. Puente, D. Castellano, J.F. Rodriguez-Moreno, E. Esteban, E. Grande Pulido, E.M. Fernandez Parra, L. Rodriguez Lajusticia, M. Domenech, E. Gonzalez Billalabeitia, M.I. Sáez, E. Gallardo Diaz, S. Hernando Polo, A. Herrador, L. Inglada-Pérez, M. Robledo, C. Rodriguez-Antona
Journal: Annals of Oncology (2017)
The Importance of Breakfast in Atherosclerosis Disease
Authors: Irina Uzhova, Valentín Fuster, Antonio Fernández-Ortiz, José M. Ordovás, Javier Sanz, Leticia Fernández-Friera, Beatriz López-Melgar, José M. Mendiguren, Borja Ibáñez, Héctor Bueno, José L. Peñalvo
Journal: Journal of the American College of Cardiology (2017)
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Authors: Eskil Eskilsson, Gro V Røsland, Gergely Solecki, Qianghu Wang, Patrick N Harter, Grazia Graziani, Roel G W Verhaak, Frank Winkler, Rolf Bjerkvig, Hrvoje Miletic
Journal: Neuro-Oncology (2017)

Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need of effective treatment strategies. Recent advances in sequencing techniques unraveled the complete genomic landscape of GBMs and revealed profound heterogeneity of individual tumors even at the single cell level. Genomic profiling has detected epidermal growth factor receptor (EGFR) gene alterations in more than half of GBMs. Major genetic events include amplification and mutation of EGFR. Yet, treatment strategies targeting EGFR have thus far failed in clinical trials. In this review, we discuss the clonal and functional heterogeneity of EGFRs in GBM development and critically reassess the potential of EGFRs as therapeutic targets.
Refining staging system for nasopharyngeal carcinoma treated with intensity-modulated radiation therapy
Authors: V.H-F. Lee, D.L-W. Kwong, T.W. Leung, C-W. Choi, B. O'Sullivan, K.O. Lam, V. Lai, P-L. Khong, S-K. Chan, C-Y. Ng, C.C. Tong, P.Y.P. Ho, W.L. Chan, L-S. Wong, D.K-C. Leung, S-Y. Chan, A.W-M. Lee
Journal: Annals of Oncology (2017)
Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration
Authors: A. Necchi, S. Lo Vullo, L. Mariani, M. Moschini, K. Hendricksen, M. Rink, R. Sosnowski, J. Dobruch, J.D. Raman, C.G. Wood, V. Margulis, M. Rouprêt, A. Briganti, F. Montorsi, E. Xylinas, S.F. Shariat
Journal: Annals of Oncology (2017)
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
Authors: Edward S. Kim, Suanna S. Bruinooge, Samantha Roberts, Gwynn Ison, Nancy U. Lin, Lia Gore, Thomas S. Uldrick, Stuart M. Lichtman, Nancy Roach, Julia A. Beaver, Rajeshwari Sridhara, Paul J. Hesketh, Andrea M. Denicoff, Elizabeth Garrett-Mayer, Eric Rubin, Pratik Multani, Tatiana M. Prowell, Caroline Schenkel, Marina Kozak, Jeff Allen, Ellen Sigal, Richard L. Schilsky
Journal: Journal of Clinical Oncology (2017)

Purpose The primary purposes of eligibility criteria are to protect the safety of trial participants and define the trial population. Excessive or overly restrictive eligibility criteria can slow trial accrual, jeopardize the generalizability of results, and limit understanding of the intervention's benefit-risk profile. Methods ASCO, Friends of Cancer Research, and the US Food and Drug Administration examined specific eligibility criteria (ie, brain metastases, minimum age, HIV infection, and organ dysfunction and prior and concurrent malignancies) to determine whether to modify definitions to extend trials to a broader population. Working groups developed consensus recommendations based on review of evidence, consideration of the patient population, and consultation with the research community. Results Patients with treated or clinically stable brain metastases should be routinely included in trials and only excluded if there is compelling rationale. In initial dose-finding trials, pediatric-specific cohorts should be included based on strong scientific rationale for benefit. Later phase trials in diseases that span adult and pediatric populations should include patients older than age 12 years. HIV-infected patients who are healthy and have low risk of AIDS-related outcomes should be included absent specific rationale for exclusion. Renal function criteria should enable liberal creatinine clearance, unless the investigational agent involves renal excretion. Patients with prior or concurrent malignancies should be included, especially when the risk of the malignancy interfering with either safety or efficacy endpoints is very low. Conclusion To maximize generalizability of results, trial enrollment criteria should strive for inclusiveness. Rationale for excluding patients should be clearly articulated and reflect expected toxicities associated with the therapy under investigation.